MedPath

Tamnorzatinib

Generic Name
Tamnorzatinib
Clinical Trials
Related News

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Pancreatic Cancer
Interventions
First Posted Date
2024-08-01
Last Posted Date
2025-04-18
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
87
Registration Number
NCT06532331
Locations
🇯🇵

Aichi Cancer Center, Nagoya-shi, Aichi, Japan

🇯🇵

National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

🇯🇵

Kanazawa University Hospital, Kanazawa-shi, Ishikawa, Japan

and more 6 locations

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Phase 1
Active, not recruiting
Conditions
Stage IIIB Non-small Cell Lung Cancer
Stage IIIC Non-Small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Cancer
EGFR Mutation-Related Tumors
Interventions
First Posted Date
2024-07-29
Last Posted Date
2024-10-08
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
78
Registration Number
NCT06525246
Locations
🇯🇵

Kobe City Medical Center General Hospital, Kobe-shi, Hyogo, Japan

🇯🇵

The Cancer Institute Hospital Of JFCR, Koto-Ku, Tokyo, Japan

🇯🇵

Hyogo College Of Medicine College Hospital, Nishinomiya, Hyogo, Japan

and more 10 locations

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Advanced or Metastatic Solid Tumors
Interventions
Drug: ONO-7475 + ONO-4538
First Posted Date
2018-11-05
Last Posted Date
2023-10-04
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
24
Registration Number
NCT03730337
Locations
🇯🇵

Tokyo Clinical Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy